论文部分内容阅读
２年手术治疗肺癌５５例，术后病理分期，Ⅲ期肺癌２８例（占５０．９％），其中Ⅲ＿ｂ期３例。术前有７例行支气管动脉灌注化疗。２８例中，手术切除１９例，占６７．９％，无手术死亡。２年随访，中位存活期１１个月。２年累积存活率６９．０％。本文提出了Ⅲ期肺癌各亚组的手术适应证，包括（１）周围型肺癌侵犯壁层胸膜或胸壁或伴有Ｎ＿２者；（２）、中央型肺癌距隆重＜２．０ｃｍ者，或肿瘤侵犯上腔静脉或肺血管主干者；（３）小细胞肺癌属于Ｔ＿３Ｎ＿（０－１）Ｍ＿０者。
Two years of surgical treatment of lung cancer in 55 cases, postoperative pathological stage, stage III lung cancer in 28 cases (50.9%), including III_b of 3 cases. Seven patients underwent bronchial arterial infusion chemotherapy before surgery. Among the 28 cases, 19 cases were surgical resection, accounting for 67.9%, and no operative death occurred. After 2 years of follow-up, the median survival period was 11 months. The 2-year cumulative survival rate was 69.0%. This article presents surgical indications for each subgroup of patients with stage III lung cancer, including (1) peripheral lung cancer invading the parietal pleura or chest wall or with N_2; (2) central lung cancer with apical <2.0 cm, or tumor Invade the superior vena cava or pulmonary vascular trunk; (3) small cell lung cancer belongs to T_3N_ (0-1) M_0.